Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men-United States, 2016-2018

Elissa Meites¹, Rachel L Winer², Michael E Newcomb³, Pamina M Gorbach⁴, Troy D Querec⁵, Jessica Rudd⁶, Tom Collins⁷, John Lin², Janell Moore⁴, Thomas Remble³, Fred Swanson⁸, Justin Franz³, Robert K Bolan⁹, Matthew R Golden¹⁰, Brian Mustanski³, Richard A Crosby⁷, Elizabeth R Unger⁵, Lauri E Markowitz¹

Affiliations

¹ Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² Department of Epidemiology, University of Washington, Seattle, Washington, USA.
³ Institute for Sexual and Gender Minority Health and Wellbeing and Department of Medical Social Sciences, Northwestern University and Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁴ Department of Epidemiology, Fielding School of Public Health, University of California at Los Angeles, Los Angeles, California, USA.
⁵ Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
⁶ Maximus Services LLC, CDC Contractor, Atlanta, Georgia, USA.
⁷ College of Public Health, University of Kentucky, Lexington, Kentucky, USA.
⁸ Gay City Health Project, Seattle, Washington, USA.
⁹ Los Angeles LGBT Center, Los Angeles, California, USA.
¹⁰ Center for AIDS & STD, University of Washington, Seattle, Washington, USA.

PMID: 32504091
PMCID: PMC7669535
DOI: 10.1093/infdis/jiaa306

Free PMC article

Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men-United States, 2016-2018

Elissa Meites et al. J Infect Dis. 2020.

Free PMC article

. 2020 Nov 13;222(12):2052-2060.

doi: 10.1093/infdis/jiaa306.

Authors

Affiliations

¹ Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² Department of Epidemiology, University of Washington, Seattle, Washington, USA.
³ Institute for Sexual and Gender Minority Health and Wellbeing and Department of Medical Social Sciences, Northwestern University and Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁴ Department of Epidemiology, Fielding School of Public Health, University of California at Los Angeles, Los Angeles, California, USA.
⁵ Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
⁶ Maximus Services LLC, CDC Contractor, Atlanta, Georgia, USA.
⁷ College of Public Health, University of Kentucky, Lexington, Kentucky, USA.
⁸ Gay City Health Project, Seattle, Washington, USA.
⁹ Los Angeles LGBT Center, Los Angeles, California, USA.
¹⁰ Center for AIDS & STD, University of Washington, Seattle, Washington, USA.

PMID: 32504091
PMCID: PMC7669535
DOI: 10.1093/infdis/jiaa306

Abstract

Background: In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011.

Methods: The Vaccine Impact in Men study surveyed MSM and transgender women aged 18-26 years in 3 US cities during 2016-2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI).

Results: Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at age ≤18 years was 0.41 (CI, 0.24-0.57) and at age >18 years was 0.82 (CI, 0.67-0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at age ≤18 years or >18 years was 59% and 18%, respectively.

Conclusions: Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination.

Keywords: papillomavirus infections; papillomavirus vaccines; sexual and gender minorities; vaccination.

Published by Oxford University Press for the Infectious Diseases Society of America 2020.

PubMed Disclaimer

References

1. MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30 - PubMed
1. Lancet Oncol. 2012 May;13(5):487-500 - PubMed
1. PLoS One. 2015 Jul 06;10(7):e0132404 - PubMed
1. MMWR Morb Mortal Wkly Rep. 2012 Aug 31;61(34):671-7 - PubMed
1. J Natl Cancer Inst. 2013 Apr 3;105(7):469-74 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men-United States, 2016-2018

Affiliations

Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men-United States, 2016-2018

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous